Dr. med. Michael Montemurro

Consultant, Medical Oncology - University College London Hospitals, UK

Chief Physician, Medical Oncology – EHC Morges Hospital, CH

Deputy Physician, Medical Oncology - CHUV Lausanne, CH

Associate Physician, Medical Oncology - IOSI-EOC, Ospedale Bellinzona, CH

Sarcoma Unit, The Royal Marsden Hospital London, UK

Medical oncology, CHU Zurich, CH

Multidisciplinary Oncology Center (CePO), CHUV Lausanne, CH

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Montemurro M, 2021 Feb;27(2):289-300

Prediction of tumor grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001

LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Montemurro, M., et al. Cell Rep. 2020 Mar 31;30(13):4567-4583

Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma
Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Rüdiger , Cherix Eur J Surg Oncol. 2020 May;46(5):898-904

Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ....
Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Schäfer M, Halkic N, Demartines N.  BMC Surg. 2020 Apr 19;20(1):78

Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer...
De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084

Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).
Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454

Sarcoma of the heart: survival after surgery.
Niclauss L, Montemurro M, Kirsch M, Prêtre R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201

Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study
Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8

Survival after surgical drainage of malignant pericardial effusion Niclauss L, Montemurro M, Prêtre R; World J Surg 2015 Jul;39(7):1767

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour .....
M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31

Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.

Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST
Prior JO, Montemurro M et al.; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8. Nilotinib in the treatment of advanced gastrointestinal stromal tumors resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7

PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell
transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.

Book chapter

Principles of Tumor Therapy
In: “HEROLD – INNERE MEDIZIN”, Gerd Herold (editor), Germany; since 2010, annual update

ESMO Exam Medical Oncology

Internal hematology and oncology

Internal Medicine

Research thesis, Faculty of Medicine, Essen University, Germany

Medical studies, Johann Wolfgang Goethe Universität, Frankfurt, Germany